#1 Clinical Trials Search in Europe

Sulfamethoxazole

Sulfamethoxazole is an antibiotic medication that is commonly used in combination with trimethoprim (often abbreviated as TMP-SMX) for treating various bacterial infections and as a preventive measure against certain opportunistic infections. This article explores the use and effectiveness of sulfamethoxazole in clinical trials for different medical conditions.

Table of Contents

What is Sulfamethoxazole?

Sulfamethoxazole is an antibiotic medication that is often used in combination with another antibiotic called trimethoprim. This combination is known as co-trimoxazole, and it’s commonly referred to by brand names such as Bactrim, Septra, or Sulfatrim[1][2]. Sulfamethoxazole belongs to a class of drugs called sulfonamides, which are synthetic antibiotics used to treat various bacterial infections[1].

Uses of Sulfamethoxazole

Sulfamethoxazole, typically in combination with trimethoprim, is used to treat a wide variety of bacterial infections. Some of the common conditions it’s used for include:

  • Urinary tract infections (UTIs): It’s effective against bacteria that cause UTIs[3].
  • Pneumocystis jirovecii pneumonia (PJP): This is a type of pneumonia that often affects people with weakened immune systems, such as those with HIV/AIDS[4].
  • Skin infections: Including abscesses caused by bacteria like Staphylococcus aureus[2].
  • Ear infections, bronchitis, and traveler’s diarrhea[1].
  • Prevention of infections: In some cases, it’s used to prevent infections in people with weakened immune systems or certain chronic conditions[5].

How Sulfamethoxazole Works

Sulfamethoxazole works by interfering with the ability of bacteria to produce folic acid, which is essential for their growth and reproduction. When combined with trimethoprim, the two drugs work together to block different steps in the bacterial folic acid synthesis pathway, making the combination more effective than either drug alone[1].

Dosage and Administration

The dosage of sulfamethoxazole can vary depending on the specific condition being treated, the patient’s age, weight, and other factors. It’s typically taken orally in tablet form, but can also be given intravenously in some cases. For example:

  • For treating skin abscesses in children, a common dose is 10 mg of trimethoprim per kg of body weight per day, divided into two doses, for 3 to 10 days[2].
  • For preventing Pneumocystis jirovecii pneumonia in adults with certain conditions, a dose of 80 mg trimethoprim/400 mg sulfamethoxazole taken daily may be used[5].

It’s crucial to take the medication exactly as prescribed by your healthcare provider and complete the full course of treatment, even if you start feeling better before it’s finished.

Effectiveness of Sulfamethoxazole

Sulfamethoxazole, especially when combined with trimethoprim, has been shown to be effective in treating and preventing various infections. For instance:

  • It has been found effective in reducing the rate of urinary tract infections in pregnant women with recurrent infections[3].
  • In treating skin abscesses, a study found that 3 days of treatment was as effective as 10 days in most cases[2].
  • It’s been shown to be effective in preventing Pneumocystis jirovecii pneumonia in patients with weakened immune systems[5].

Side Effects and Safety

Like all medications, sulfamethoxazole can cause side effects. Common side effects may include:

  • Nausea, vomiting, or loss of appetite
  • Skin rashes or itching
  • Headache
  • Dizziness

More serious side effects, though less common, can include severe skin reactions, liver problems, or blood disorders. It’s important to seek medical attention if you experience any unusual or severe side effects[6].

Special Considerations

There are several important considerations when using sulfamethoxazole:

  • Pregnancy: The safety of sulfamethoxazole during pregnancy is not fully established. Always consult with your healthcare provider if you’re pregnant or planning to become pregnant[3].
  • Kidney function: The dosage may need to be adjusted in people with kidney problems[1].
  • Allergies: People with known allergies to sulfa drugs should not take sulfamethoxazole.
  • Drug interactions: Sulfamethoxazole can interact with other medications, so it’s important to inform your healthcare provider about all medications you’re taking.

Remember, while this information provides a general overview, it’s crucial to consult with your healthcare provider for personalized advice and information about using sulfamethoxazole.

Aspect Details
Primary Uses Treatment and prevention of Pneumocystis jirovecii pneumonia (PJP), skin abscesses, prophylaxis in immunocompromised patients
Common Dosage Forms Oral tablets, suspension; usually combined with trimethoprim (TMP-SMX)
Target Populations HIV patients, those with autoimmune diseases, patients on immunosuppressive treatments
Effectiveness Shown to be effective in preventing PJP and treating various bacterial infections
Side Effects Nausea, skin rashes, liver enzyme abnormalities; rare severe reactions possible
Research Focus Optimal dosing regimens, duration of treatment, use in specific patient populations

FAQ

  • What is sulfamethoxazole primarily used for in clinical trials? Sulfamethoxazole is primarily used in clinical trials for treating or preventing various infections, including Pneumocystis jirovecii pneumonia (PJP), skin abscesses, and as a prophylactic treatment in immunocompromised patients with conditions like HIV or autoimmune diseases.
  • How is sulfamethoxazole typically administered in clinical trials? In most clinical trials, sulfamethoxazole is administered orally in combination with trimethoprim (TMP-SMX). The dosage and duration vary depending on the condition being treated or prevented, ranging from daily doses to every other day regimens.
  • What are some potential side effects of sulfamethoxazole observed in clinical trials? Some potential side effects observed in clinical trials include nausea, vomiting, skin rashes, liver enzyme abnormalities, and in rare cases, more severe reactions like drug-induced liver injury or cytopenia. The frequency and severity of side effects often depend on the dosage and duration of treatment.
  • Are there any specific patient populations that benefit most from sulfamethoxazole in clinical trials? Clinical trials have shown that sulfamethoxazole is particularly beneficial for immunocompromised patients, such as those with HIV, autoimmune diseases, or those undergoing immunosuppressive treatments. It's also been studied in patients with certain rheumatic diseases and skin infections.
  • How does sulfamethoxazole compare to other treatments in clinical trials? In many clinical trials, sulfamethoxazole (usually in combination with trimethoprim) has shown to be effective for preventing opportunistic infections like PJP. Some studies have compared different dosing regimens or durations of treatment to optimize its use while minimizing side effects.

Ongoing Clinical Trials on Sulfamethoxazole

  • Study on Antibiotic Treatments for Kidney Infection in Children: Comparing Cefixime, Ceftriaxone, and Amikacin for Ages 1 Month to 3 Years

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia Hungary

  • Study on Antibiotic Treatment for Hip and Knee Joint Infections Using Linezolid, Fusidic Acid, and Rifampicin

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study Comparing Oral Fluoroquinolones or Trimethoprim-Sulfamethoxazole to IV Therapy in Stable Patients with Gram-Negative Blood Infections

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Greece Italy Spain

  • Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

  • Study on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

Glossary

  • Pneumocystis jirovecii pneumonia (PJP): A type of pneumonia caused by a fungus, which primarily affects people with weakened immune systems. It's a common opportunistic infection in HIV/AIDS patients and others with compromised immunity.
  • Prophylaxis: Preventive treatment to stop a disease from occurring. In many trials, sulfamethoxazole is used as prophylaxis against certain infections in high-risk patients.
  • Trimethoprim-sulfamethoxazole (TMP-SMX): A combination antibiotic medication containing trimethoprim and sulfamethoxazole, commonly used to treat various bacterial infections and prevent opportunistic infections in immunocompromised patients.
  • Immunocompromised: Having a weakened immune system, which can be due to diseases like HIV/AIDS, certain medications, or other health conditions. These patients are often at higher risk for opportunistic infections.
  • Autoimmune Inflammatory Rheumatic Disease (AIIRD): A group of diseases characterized by the immune system attacking the body's own tissues, often affecting joints, muscles, and other organs.
  • Granulomatosis with polyangiitis (GPA): A rare autoimmune disease that causes inflammation of blood vessels in the nose, sinuses, throat, lungs, and kidneys.
  • Cytopenia: A medical condition in which there is a reduction in the number of mature blood cells of a particular type. This can be a potential side effect of some medications.
  • Retinochoroiditis: Inflammation of the retina and choroid of the eye, which can be caused by various factors including infections like toxoplasmosis.

References

  1. https://clinicaltrials.gov/study/NCT01167452
  2. https://clinicaltrials.gov/study/NCT02024867
  3. https://clinicaltrials.gov/study/NCT01507974
  4. https://clinicaltrials.gov/study/NCT04851015
  5. https://clinicaltrials.gov/study/NCT01747278
  6. https://clinicaltrials.gov/study/NCT06499233